Relationship Between Multimorbidity, Combination and All-Cause Mortality Among Older Adults: A Retrospective Cohort Analysis

Kun He
Zhengzhou University

Wenli Zhang
Zhengzhou University

Xueqi Hu
Zhengzhou University

Hao Zhao
Zhengzhou University

Bingxin Guo
Zhengzhou university

Zhan Shi
Zhengzhou First People Hospital

Xiaoyan Zhao
Chinese PLA General Hospital

Chunyu Yin
Chinese PLA General Hospital

Songhe Shi (✉ zzussh@126.com)
Zhengzhou University  https://orcid.org/0000-0002-2214-1440

Research article

Keywords: Older adults, Chronic conditions, Multimorbidity, All-cause mortality, Combination

DOI: https://doi.org/10.21203/rs.3.rs-122536/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Previous studies have evaluated the association of multimorbidity with higher mortality, but epidemiologic data on the association between the combination of multimorbidity and all-cause mortality risk are rare. We aimed to examine the relationship between multimorbidity (number/combination) and all-cause mortality in Chinese older adults.

Methods: We conducted a population-based study of 50,100 Chinese participants. Cox regression models were used to estimate the impact of long-term conditions (LTCs) on all-cause mortality.

Results: The prevalence of multimorbidity was 31.35% and all-cause mortality was 8.01% (50,100 participants). In adjusted Cox models, the hazard ratios (HRs) and 95% confidence intervals (CIs) of all-cause mortality risk for those with 1, 2, and ≥ 3 LTCs compared with those with no LTCs was 1.10 (1.01-1.20), 1.21 (1.10-1.33), and 1.46 (1.27-1.67), respectively ($P_{\text{trend}} < 0.001$). In the LTCs ≥ 2 category, the combination of chronic diseases that included hypertension, diabetes, CHD, COPD, and stroke had the greatest impact on mortality. In the stratified model by age and sex, absolute all-cause mortality was higher among the ≥ 75 age group with an increasing number of LTCs. However, the relative effect size of the increasing number of LTCs on higher mortality risk was larger among those < 75 years.

Conclusions: The risk of all-cause mortality is increased with the number of multimorbidity among Chinese older adults, particularly combinations.

Background

Aging around the world poses a global challenge, previous studies have reported that thousands of persons turn 65 years old every day[1]. To our knowledge, China has the largest population base in the world, and the size of the elderly population is enormous. In 2018, the number of Chinese people aged 65 or above had reached 166.58 million, accounting for 11.9% of the total population, which means that China is aging at an unprecedented rate[2]. The phenomenon of ageing has led to a substantial increase in chronic conditions, which consequently results in a rising prevalence of multimorbidity, most commonly described as the presence of two or more long-term conditions (LTCs)[3]. Studies have found that multimorbidity leads to poor quality of life[4], increased use of inpatient and ambulatory greater health care[5, 6], greater complexity regarding of clinical treatment and patient management[7, 8], and more importantly, an increase in mortality[9, 10]. For example, previous studies, mainly based on the UK population, had suggested that the all-cause mortality rate for people with multimorbidity was 4.74% [11]. Thus, the management of multimorbidity has become a public health priority for public health care professionals and health care systems[7, 12].

The study found that hypertension, diabetes, stroke, heart disease, chronic respiratory disease and cancer are among the most common types of multimorbidity and are the most common causes of long-term disability and premature mortality worldwide[13–16]. As a result of the change of healthy lifestyle and the progress of medical level, the mortality rate from multimorbidity such as heart disease and cancer
has been significantly reduced in high-income countries[17, 18], whereas rates of mortality caused by multimorbidity are rising rapidly in low- and middle-income countries, posing a serious social burden[19].

Thus, a better understanding of the epidemiology of multimorbidity is necessary to develop interventions to reduce the burden of death. However, the relationship between multimorbidity (number/combination) and all-cause mortality has not been well described in the Chinese population. Therefore, we designed a retrospective cohort study to explore the relationship in Chinese older adults.

Methods

Study design and participants

We performed a retrospective cohort analysis of 103,729 participants who entered the health check-up program in Xinzheng City, Henan Province, Central China, from January 1, 2014 to November 15, 2019. A total of 84,353 (81.3%) participants were successfully followed up. We excluded participants with age < 65 at baseline (n = 31,900), or missing data for date of birth and gender at baseline (n = 2,353). A total of 50,100 individuals were included in the main analysis (Supplemental Fig. 1). The study was approved by the Ethics Committee of Zhengzhou University, and written informed consent was obtained from all participants.

Data Collection

A standardized questionnaire was used by trained research staff under stringent quality control to collect information. Marital status was categorized as living with partner and without partner. Smokers were defined as ever smoking at least 100 cigarettes in their lifetime and classified as nonsmokers and previous/current smokers[20]. Alcohol consumption was divided into three categories: never, occasionally or daily. Physical activity was a categorical variable based on the self-reporting and classified as never, occasionally or daily. The measurements for height and weight were performed with the subjects wearing light clothing without shoes[21]. Blood pressure was measured by an automatic sphygmomanometer (Omron HEM-7125, Kyoto, Japan) after subjects had rested in a seated position for at least 5 minutes, and the mean value was recorded when the subjects were measured three times[22]. Blood samples were obtained after an overnight fast of at least 8 hours to assess levels of fasting plasma glucose (FPG) using an automatic biochemical analyzer (DIRUI CS380, Changchun, China)[22]. In this study, diabetes was defined as fasting glucose levels ≥ 7.0 mmol/L and/or current treatment with anti-diabetes medication according to the China guideline for T2DM[23]. Hypertension was defined as positive for participants who were considered hypertensive with systolic blood pressure (SBP) ≥ 140 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg or current use of antihypertensive medication[24]. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²), which was classified based on the WHO classification criteria into underweight (< 18.5 kg/m²), desirable (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), obesity class I (30.0–34.9 kg/m²), obesity class II (35.0–39.9 kg/m²), and obesity
class III (≥ 40.0 kg/m²)[25]. Information on the 7 chronic conditions diagnosed by a physician or reported by the study participants was recorded: (1) hypertension, (2) diabetes, (3) coronary heart disease (CHD), (4) stroke, (5) chronic obstructive pulmonary disease (COPD), (6) cancer, and (7) mental system disease. Multimorbidity was classified based on number of chronic conditions into no LTCs, 1 LTC, 2 LTCs, and ≥ 3 LTCs. The outcome variable for the present study was all-cause mortality. Death certificates were obtained as well.

**Statistical analysis**

All quantitative variables are described using the median (interquartile range [IQR]) for skewed distribution, and qualitative variables are expressed as frequency (%). Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of all-cause mortality by groups of LTC categories. With no LTCs as the reference group, we constructed three multivariate-adjusted Cox models: model 1 was adjusted for age, sex and marital status; model 2 was adjusted for model 1 plus smoking status, alcohol status and physical activity; and model 3 was further adjusted for BMI. In order to understand the pattern and effect of multimorbidity, we further analyzed the common combination of multimorbidity in older adults. A test for multiplicative interaction showed that age (< 75/≥ 75 years) and sex at baseline modified the association of LTCs and risk of all-cause mortality (both $p$-interaction < 0.001). Therefore, for subgroup analyses, we stratified participants by age and sex at baseline. Finally, sensitivity analysis was performed using LTCs defined by the medical examination diagnostic record at study baseline and not including self-reported history. Statistical analyses were performed using SAS 9.1 (SAS Institute, Cary, NC, USA), the forest plot was performed by GraphPad Prism 8, and the level of significance was considered at $P < 0.05$ (two-tailed).

**Results**

The baseline characteristics of study participants with the four LTC groups are presented in Table 1. A total of 4,012 (8.01%) of the 50,100 participants died. The median age at baseline was 69.18 years (range 65–106 years), and 53.87% of the population was female. The proportion of participants with 0, 1, 2, and 3 or more LTCs was 12,334 (24.62%), 22,060 (44.03%), 12,866 (25.68%), and 2,840 (5.67%), respectively. In addition, the prevalence of multimorbidity in female was higher than in male (67.47% vs 63.58%). The most frequent diseases in participants with 3 or more LTCs were hypertension (98.87%), CHD (89.65%), and diabetes (88.59%).
|                     | No LTCs | 1 LTC       | 2 LTCs       | ≥ 3 LTCs     | Over all     |
|---------------------|---------|-------------|--------------|--------------|--------------|
|                     | N = 12,334 (24.62%) | N = 22,060 (44.03%) | N = 12,866 (25.68%) | N = 2,840 (5.67%) | N = 50,100   |
| Age; missing values n = 0 | 68.85 (65.95–75.04) | 69.35 (65.98–75.69) | 69.20 (65.95–75.42) | 69.15 (65.88–75.19) | 69.18 (65.96–75.46) |
| Age in years - median (IQR) | 69.35 (65.98–75.69) | 69.20 (65.95–75.42) | 69.15 (65.88–75.19) | 69.18 (65.96–75.46) |  |
| Sex; missing values n = 0 | 6,394 (51.84) | 10,437 (47.31) | 5,244 (40.76) | 1,034 (36.41) | 23,109 (46.13) |
| Male                | 5,940 (48.16) | 11,623 (52.69) | 7,622 (59.24) | 1,806 (63.59) | 26,991 (53.87) |
| Female              | 9,852 (80.11) | 17,180 (78.09) | 10,117 (78.88) | 2,215 (78.13) | 39,364 (78.79) |
| Marital status; missing values n = 140 (0.28%) | 2,446 (19.89) | 4,821 (21.91) | 2,709 (21.12) | 620 (21.87) | 10,596 (21.21) |
| Living with partner |         |             |              |              |              |
| Living without partner |       |             |              |              |              |
| Smoking status; missing values n = 614 (1.24%) | 10,171 (84.50) | 18,402 (84.31) | 11,122 (86.94) | 2,475 (87.46) | 42,170 (85.21) |
| Never               | 1,865 (15.50) | 3,425 (15.69) | 1,671 (13.06) | 355 (12.54) | 7,316 (14.78) |
| Current or previous |         |             |              |              |              |
| Alcohol status; missing values n = 767 (1.55%) | 11,224 (93.53) | 20,243 (93.02) | 11,903 (93.3) | 2,634 (93.40) | 46,004 (93.25) |
| Never               | 499 (4.16) | 931 (4.28) | 490 (3.84) | 107 (3.79) | 2,027 (4.11) |
| Occasionally        | 278 (2.32) | 589 (2.71) | 356 (2.79) | 79 (2.80) | 1,302 (2.64) |
| Daily               |         |             |              |              |              |

LTCs, long-term conditions; IQR, interquartile range; BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
|                        | No LTCs                                      | 1 LTC                                        | 2 LTCs                                       | ≥ 3 LTCs                                     | Over all                                   |
|------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------|
|                        | N=12,334(24.62%)                             | N=22,060(44.03%)                             | N=12,866(25.68%)                             | N=2,840(5.67%)                               | N=50,100                                   |
| Physical activity;    | 8,404 (69.78)                                | 13,860 (63.71)                               | 7,678 (60.18)                                | 1,676 (59.41)                                | 31,618 (64.03)                             |
| missing values n=723(1.46%)| 1,085 (9.01)                                | 2,351 (10.81)                               | 1,434 (11.24)                                | 306 (10.85)                                  | 5,176 (10.48)                              |
| Never                  | 2,554 (21.21)                                | 5,543 (25.48)                               | 3,647 (28.58)                                | 839 (29.74)                                  | 12,583 (25.48)                             |
| Occasionally           |                                              |                                              |                                              |                                              |                                            |
| Daily                  |                                              |                                              |                                              |                                              |                                            |
| BMI; missing values n= | 336 (2.82)                                   | 407 (1.90)                                   | 173 (1.37)                                   | 34 (1.22)                                    | 950 (1.95)                                 |
| 1,323(2.71%)           | 8,091 (68.00)                                | 11,943 (55.62)                               | 5,833 (46.24)                                | 1,215 (43.53)                                | 27,082 (55.52)                             |
| <18.5                  | 3,129 (26.30)                                | 7,612 (35.45)                                | 5,306 (42.06)                                | 1,187 (42.53)                                | 17,234 (35.33)                             |
| 18.5–24.9              | 324 (2.72)                                   | 1,378 (6.42)                                 | 1,175 (9.31)                                 | 316 (11.32)                                  | 17,193 (35.57)                             |
| 25-29.9                | 15 (0.13)                                    | 122 (0.57)                                   | 114 (0.90)                                   | 316 (11.32)                                  | 17,234 (35.33)                             |
| 30-34.9                | 3 (0.03)                                     | 11 (0.05)                                    | 14 (0.11)                                    | 36 (1.29)                                    | 287 (0.59)                                 |
| 35-39.9                |                                              |                                              |                                              | 3 (0.11)                                     | 287 (0.59)                                 |
| ≥ 40                   |                                              |                                              |                                              |                                              | 31 (0.06)                                  |
| Chronic conditions     | 0 (0.00)                                     | 17,057 (77.32)                               | 12,162 (94.53)                               | 2,808 (98.87)                                | 32,027 (63.93)                             |
| Hypertension           | 0 (0.00)                                     | 2,242 (10.16)                                | 6,962 (54.11)                                | 2,516 (88.59)                                | 11,720 (23.39)                             |
| Diabetes               | 0 (0.00)                                     | 2,420 (10.97)                                | 5,714 (44.41)                                | 2,546 (89.65)                                | 10,680 (21.32)                             |
| CHD                    | 0 (0.00)                                     | 77 (0.35)                                    | 424 (3.30)                                   | 2,546 (89.65)                                | 10,680 (21.32)                             |
| Stroke                 | 0 (0.00)                                     | 157 (0.71)                                   | 352 (2.74)                                   | 425 (14.96)                                  | 425 (14.96)                                |
| COPD                   | 0 (0.00)                                     | 18 (0.08)                                    | 22 (0.17)                                    | 266 (9.37)                                   | 266 (9.37)                                 |
| Tumour                 | 0 (0.00)                                     | 79 (0.36)                                    | 93 (0.72)                                    | 17 (0.60)                                    | 17 (0.60)                                  |
| Mental disorders       |                                              |                                              |                                              |                                              | 81 (2.85)                                  |
|                        |                                              |                                              |                                              |                                              | 57 (0.11)                                  |

LTCs, long-term conditions; IQR, interquartile range; BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
During 205,022.95 person-years of follow-up, the mortality rates (per 1,000 person-years) were 15.92, 19.83, 21.18, and 24.80 in the no LTCs, 1 LTC, 2 LTCs, and ≥ 3 LTCs groups, respectively. The number of LTCs at baseline had a significant association with all-cause mortality observed in the three models (Table 2). In adjusted Cox model 3, the HRs (95% CIs) for all-cause mortality in participants with 1, 2, and ≥ 3 LTCs compared with those with no LTCs were 1.10 (1.01–1.20), 1.21 (1.10–1.33), and 1.46 (1.27–1.67), respectively ($P_{trend} < 0.001$).

### Table 2
Multimorbidity and all-cause mortality

| No LTCs | 1 LTC | 2 LTCs | ≥ 3 LTCs | $P_{trend}$ |
|---------|-------|--------|----------|-------------|
| No. of deaths | 760 | 1,809 | 1,146 | 297 |
| No. of person-years | 47,741.92 | 91,206.57 | 54,098.89 | 11,975.57 |
| Cumulative mortality rate | 15.92 | 19.83 | 21.18 | 24.80 |
| HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Model 1 | Reference | 1.04 (0.95,1.13) | 1.11 (1.02,1.22) | 1.33 (1.17,1.53) | < 0.001 |
| Model 2 | Reference | 1.06 (0.98,1.16) | 1.15 (1.05,1.26) | 1.38 (1.20,1.58) | < 0.001 |
| Model 3 | Reference | 1.10 (1.01,1.20) | 1.21 (1.10,1.33) | 1.46 (1.27,1.67) | < 0.001 |

LTCs, long-term conditions, HR denotes hazard ratio and 95% CI denotes 95% confidence interval.

- **a** Per 1000 person-years.
- **b** Model 1 is adjusted for age (< 75 or ≥ 75), sex (female or male) and marital status (living with partner or living without partner).
- **c** Model 2 is adjusted for covariates in model 1 plus smoking status (never, current or previous) and alcohol status (never, occasions or daily).
- **d** Model 3 is adjusted for covariates in model 2 plus body mass index (< 18.5, 18.5–24.9, 25–29.9, 30–34.9, 35–39.9 or ≥ 40).

In the study, we assessed the impact of 16 different combinations of 7 chronic diseases on the risk of all-cause mortality, as shown in Table 3. In the LTCs = 2 category, the combination of hypertension + diabetes (HR 1.32, 95% CI 1.18–1.48), hypertension + stroke (HR 1.69, 95% CI 1.27–2.26), hypertension + COPD (HR 1.91, 95% CI 1.40–2.62), and diabetes + COPD (HR 3.49, 95% CI 1.31–9.34) had significant effects on mortality. For those with 3 LTCs, the combination of hypertension + diabetes + CHD (HR 1.29, 95% CI 1.10–1.52), hypertension + diabetes + stroke (HR 2.52, 95% CI 1.71–3.70), and hypertension + CHD + COPD (HR 1.88, 95% CI 1.16–3.05) had significant effects on mortality. For the population with LTCs = 4,
the combination of hypertension + diabetes + CHD + stroke (HR 2.14, 95% CI 1.11–4.14) had significant effects on mortality. Hypertension appears most frequently in the combination of multimorbidity.
Table 3
The most impactful LTCs combinations in stratified Cox regression analysis for mortality, for different multimorbidity categories (based on LTC count)

| Categories                          | No. of deaths | No. of person-years | Cumulative mortality rate* | Adjusted** HR (95% CI) |
|-------------------------------------|---------------|---------------------|---------------------------|------------------------|
| 2 LTCs (Total number of deaths N = 1146) |               |                     |                           |                        |
| Hypertension + diabetes             | 570           | 26,753.84           | 21.31                     | 1.32 (1.18, 1.48)      |
| Hypertension + CHD                  | 416           | 21,575.80           | 19.28                     | 1.02 (0.90, 1.16)      |
| Hypertension + stroke               | 58            | 1,581.35            | 36.68                     | 1.69 (1.27, 2.26)      |
| Hypertension + COPD                 | 44            | 992.24              | 44.34                     | 1.91 (1.40, 2.62)      |
| Diabetes + CHD                      | 28            | 2,162.11            | 12.95                     | 0.86 (0.58, 1.26)      |
| CHD + COPD                          | 11            | 312.92              | 35.15                     | 1.37 (0.74, 2.57)      |
| Hypertension + Mental disorders     | 8             | 284.27              | 28.14                     | 1.32 (0.63, 2.79)      |
| Diabetes + COPD                     | 4             | 89.62               | 44.63                     | 3.49 (1.31, 9.34)      |
| 3 LTCs (Total number of deaths N = 279) |               |                     |                           |                        |
| Hypertension + diabetes + CHD       | 188           | 8,849.08            | 21.25                     | 1.29 (1.10, 1.52)      |
| Hypertension + diabetes + stroke    | 29            | 660.92              | 43.88                     | 2.52 (1.71, 3.70)      |
| Hypertension + stroke + CHD         | 17            | 652.11              | 26.07                     | 1.50 (0.93, 2.42)      |
| Hypertension + CHD + COPD           | 17            | 477.75              | 35.58                     | 1.88 (1.16, 3.05)      |
| Hypertension + diabetes + COPD      | 9             | 294.51              | 30.56                     | 1.54 (0.77, 3.08)      |
| 4 LTCs (Total number of deaths N = 18) |               |                     |                           |                        |

LTCs, long-term conditions;

One asterisk Per 1000 person-years;

Two asterisk adjusted for age, sex, marital status, smoking status, alcohol status, body mass index, and physical activity levels at baseline;

CHD, coronary heart disease;

COPD, chronic obstructive pulmonary disease.
| Categories                                      | No. of deaths | No. of person-years | Cumulative mortality rate* | Adjusted** HR (95% CI) |
|------------------------------------------------|---------------|---------------------|---------------------------|------------------------|
| Hypertension + diabetes + stroke + CHD         | 9             | 274.78              | 32.75                     | 2.14(1.11,4.14)        |

LTCs, long-term conditions;

One asterisk Per 1000 person-years;

Two asterisk adjusted for age, sex, marital status, smoking status, alcohol status, body mass index, and physical activity levels at baseline;

CHD, coronary heart disease;

COPD, chronic obstructive pulmonary disease.

The analysis of all-cause mortality for multimorbidity stratified by age and sex is shown in Fig. 1. In the multivariable-adjusted models, the absolute event rate for all-cause mortality was higher for the age group ≥ 75 years, but the relative effect sizes for mortality risk with increasing number of LTCs were higher for the age group < 75 years. Absolute mortality was highest in the age group ≥ 75 years with ≥ 3 LTCs (6.48% for males and 3.71% for females). However, participants in the age group < 75 years with ≥ 3 LTCs had the highest relative risk of all-cause mortality (HR 1.85, 95% CI 1.40–2.44 for males and HR 1.84, 95% CI 1.34–2.54 for females) compared to participants with no LTCs in the same age group. The observed effect size was similar for both female and male. In addition, we found that being older, living without partner, and being underweight had a higher risk of mortality. In contrast, participants who were female, overweight, class I obesity, and physically active had a significantly lower adjusted risk of all-cause mortality (Supplemental Table 1). The sensitivity analysis yielded similar findings as our main results, and the risk of death increased with the increase in LTC count when the LTC count was defined only by the physical examination records and did not include the self-reported conditions (Supplemental Table 2).

**Discussion**

This cohort study demonstrates that multimorbidity has a positive association with all-cause mortality. The results from sensitivity analyses were robust. In the LTCs ≥ 2 category, the chronic disease combination that included hypertension, diabetes, CHD, COPD, and stroke had the greatest impact on mortality. In the stratified model by age and sex, absolute all-cause mortality was higher in the age group ≥ 75 years, but the relative magnitude of the effect on mortality risk was greater among those < 75 years.

The higher all-cause mortality risk among participants with 1, 2, and ≥ 3 LTCs found in this study is consistent with previous studies that have focused on older adults[26, 27]. The study of Martinez-Gomez et al. observed significant upward trends with 1 LTC (HR 1.26), 2 LTC (HR 1.78), and ≥ 3 LTC (HR 2.27) than those without LTC[26]. Similarly, Nunes et al. conducted a meta-analysis of 26 studies and observed similar effect sizes[10]. And we also found that LTCs combinations were most strongly associated with all-cause mortality relative to the number of multimorbidity alone, whereas previous studies mainly
focused on the role of a single disease in death, such as diabetes[28]. Moreover, the present study found that hypertension was the most frequent occurrence, with presence in 11 of the 16 different combinations, suggesting that there may be a potential link between hypertension and a variety of chronic diseases. However, a large sample of participants aged 40 to 69 years study based on 36 chronic conditions showed that conditions such as hypertension, diabetes, and asthma were at the center of common multimorbidity[16]. These findings suggest there is a need for further research to explore the links between these diseases and their possible interactions, which is of great significance for the guidance and treatment of multimorbidity, and also provides a theoretical basis for the formulation of health management measures and allocation of medical resources for the elderly population to some extent.

A prospective population-based cohort study of England people aged 37 to 73 years shown that participants in the younger age group 37–49 years with ≥ 4 LTCs had the highest relative risk of all-cause mortality[11]. And we found that the association on risk of all-cause mortality with an increasing number of LTCs was particularly evident among younger age groups (< 75 vs ≥ 75 years old), which not only fills in the gap of the age of participants, but also is basically consistent with the trend of previous studies. This study found that female had a higher prevalence of multimorbidity than male, which was consistent with previous findings[29, 30]. However, the observed magnitude of mortality effect size was similar for both female and male. Potential explanations for the phenomenon are that females are generally more sensitized to their health[30], more likely to report more conditions[31], and more likely to engage in preventive health behavior[32]. These findings suggest the need for early intervention to manage and prevent chronic diseases and to reduce the prevalence of multiple diseases as much as possible.

Studies have shown that the causes of death from multimorbidity can be attributed to 4 major underlying risk factors: smoking, alcohol consumption, underweight, and physical inactivity[11, 33]. While previous studies found that smoking was a risk factor for all-cause mortality[11], our results found no statistically significant difference, which is possibly explained by the quitter bias (people may stop smoking because they are in poor health and may be advised not to continue). The results of the risk study on alcohol consumption were basically consistent with the results of Ortolá et al., which showed that there was no statistically significant difference in mortality between light-to-moderate alcohol consumption and no alcohol consumption among people over 60 years old[34]. As well, we found the greater all-cause mortality risk among persons with underweight (BMI < 18.5 kg/m²) in this study, which agreed with previous studies[21, 35, 36]. In addition, this study suggests that physical activity is associated with a lower mortality risk, and the underlying mechanism behind this finding may be that physical activity delays disease progression by preventing many chronic diseases, including diabetes, cardiovascular and respiratory diseases, and some types of cancer[37]. Therefore, once any of these chronic conditions is diagnosed, physical activity is often incorporated into treatment plans to improve quality of life and survival[26, 37, 38].

Our study has several strengths. First, the determination of chronic diseases was relatively accurate and comprehensive, including the self-reported condition of participants and the diagnosis made by the
physician based on the professional comprehensive examination. Second, our study was also novel in that we explored combinations of multimorbidity that were associated with the highest risk of death. In addition, it is more convincing to assess the relationship between multimorbidity and all-cause mortality based on a large sample size. Finally, the main results remained robust after conducting sensitivity analyses. However, the study has some limitations. Since we included only seven chronic diseases registered at baseline, some other diseases associated with older people such as hyperlipidemia and arthritis could not be taken into account, which may underestimate the prevalence of many diseases in this study, and there was no way to estimate the severity of conditions as well. Another restriction is that our participants were people over 65 years, which should caution generalizing our findings to younger age groups. In addition, although we adjusted for various covariates, there is still a possibility of residual confounding, such as diet factors. Last, recall bias is unavoidable in self-reported information.

Conclusion

Our findings suggest an increased risk of all-cause mortality with an elevated number of multimorbidity, particularly LTC combinations, which provides scientific basis for the treatment, prevention and control of the multimorbidity, and has important public health significance in guiding the rational allocation of medical and health resources.

Abbreviations

LTCs: Long-term conditions; FPG: Fasting plasma glucose; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; CHD: Coronary heart disease; COPD: Chronic obstructive pulmonary disease; IQR: Interquartile range; HRs: Hazard ratios; CIs: Confidence intervals.

Declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Zhengzhou University, and written informed consent was obtained from all participants.

Consent for Publication

Not applicable.

Availability of data and material

The datasets used and/or analyzed in this study were obtained from third parties and cannot be publicly available to confidentiality requirements.

Competing interests
The authors declare that they have no competing interests.

**Funding**

This study was supported by National Key Research and Development Program “Research on prevention and control of major chronic non-communicable diseases” of China (Grant NO: 2017YFC1307705). The funders were not involved in the study design, data collection, analysis and interpretation, and manuscript writing.

**Author contributions**

K.H., W.Z., and X.H. substantially contributed to the design and drafting of the study and the analysis and interpretation of the data. K.H. wrote the manuscript. K.H., W.Z., X.H., H.Z., B.G., Z.S., X.Z., C.Y. revised it critically for important intellectual content. All authors were involved in the collection of data and approve of the final version of the manuscript.

**Acknowledgements**

The investigators are grateful to the dedicated participants and all research staff of the study.

**Author details**

1Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China. 2Department of pharmacy, Zhengzhou people's hospital, Zhengzhou, Henan, People’s Republic of China. 3Department of Neurology, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China.

**References**

1. Cohen JE. Human population: the next half century. Science. 2003;302(5648):1172–5.

2. The 2018 Statistical Communique on National Economic and Social Development. [http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html](http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html).

3. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Home FM, Bell SP, Fulmer T, Reuben DB, Zieman S, et al. Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2018;71(19):2149–61.

4. Tyack Z, Frakes KA, Barnett A, Cornwell P, Kuys S, McPhail S. Predictors of health-related quality of life in people with a complex chronic disease including multimorbidity: a longitudinal cohort study. Quality of life research: an international journal of quality of life aspects of treatment care rehabilitation. 2016;25(10):2579–92.

5. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. The British journal of general practice: the journal of the Royal College of General Practitioners. 2011;61(582):e12–21.
6. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–76.

7. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.

8. Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. Jama. 2010;303(13):1303–4.

9. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001;54(7):661–74.

10. Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA. Multimorbidity and mortality in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2016;67:130–8.

11. Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher KI, Lee D, Mair FS. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med. 2019;17(1):74.

12. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. Jama. 2012;307(23):2493–4.

13. Marrero SL, Bloom DE, Adashi EY. Noncommunicable diseases: a global health crisis in a new world order. Jama. 2012;307(19):2037–8.

14. Bollyky TJ, Templin T, Cohen M, Dieleman JL. Lower-Income Countries That Face The Most Rapid Shift In Noncommunicable Disease Burden Are Also The Least Prepared. Health Aff. 2017;36(11):1866–75.

15. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England) 2017, 390(10100):1151–1210.

16. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN: Patterns of Multimorbidity in Middle Aged and Older Adults: An Analysis of the UK Biobank Data. Mayo Clinic proceedings 2018, 93(7):857–866.

17. Di Cesare M, Bennett JE, Best N, Stevens GA, Danaei G, Ezzati M. The contributions of risk factor trends to cardiometabolic mortality decline in 26 industrialized countries. Int J Epidemiol. 2013;42(3):838–48.

18. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. cosponsored by the American Society of Preventive Oncology. 2016;25(1):16–27.

19. Bertram MY, Sweeney K, Lauer JA, Chisholm D, Sheehan P, Rasmussen B, Upreti SR, Dixit LP, George K, Deane S. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018;391(10134):2071–8.

20. Han C, Liu Y, Sun X, Luo X, Zhang L, Wang B, Ren Y, Zhou J, Zhao Y, Zhang D, et al. Prediction of a new body shape index and body adiposity estimator for development of type 2 diabetes mellitus:
The Rural Chinese Cohort Study. Br J Nutr. 2017;118(10):771–6.

21. Cheng FW, Gao X, Mitchell DC, Wood C, Still CD, Rolston D, Jensen GL. Body mass index and all-cause mortality among older adults. Obesity (Silver Spring Md). 2016;24(10):2232–9.

22. Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, Shi S. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Scientific reports. 2019;9(1):7320.

23. Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, Zou D, Guo L, Ji Q, Chen L, et al. Standards of medical care for type 2 diabetes in China 2019. Diab/Metab Res Rev. 2019;35(6):e3158.

24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560–72.

25. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. The American journal of clinical nutrition 1998, 68(4):899–917.

26. Martinez-Gomez D, Guallar-Castillon P, Garcia-Esquinas E, Bandinelli S, Rodríguez-Artalejo F: Physical Activity and the Effect of Multimorbidity on All-Cause Mortality in Older Adults. Mayo Clinic proceedings 2017, 92(3):376–382.

27. Halonen P, Raitanen J, Jämsen E, Enroth L, Jylhä M. Chronic conditions and multimorbidity in population aged 90 years and over: associations with mortality and long-term care admission. Age Ageing. 2019;48(4):564–70.

28. Sadarangani KP, Hamer M, Mindell JS, Coombs NA, Stamatakis E. Physical activity and risk of all-cause and cardiovascular disease mortality in diabetic adults from Great Britain: pooled analysis of 10 population-based cohorts. Diabetes Care. 2014;37(4):1016–23.

29. Diaz E, Poblador-Pou B, Gimeno-Feliu LA, Calderón-Larrañaga A, Kumar BN, Prados-Torres A. Multimorbidity and Its Patterns according to Immigrant Origin. A Nationwide Register-Based Study in Norway. PloS one. 2015;10(12):e0145233.

30. Pache B, Vollenweider P, Waeber G, Marques-Vidal P. Prevalence of measured and reported multimorbidity in a representative sample of the Swiss population. BMC Public Health. 2015;15:164.

31. Verbrugge LM. The twain meet: empirical explanations of sex differences in health and mortality. Journal of health social behavior. 1989;30(3):282–304.

32. Rogers RG, Everett BG, Onge JM, Krueger PM. Social, behavioral, and biological factors, and sex differences in mortality. Demography. 2010;47(3):555–78.

33. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.

34. Ortolá R, García-Esquinas E, Lópex-García E, León-Muñoz LM, Banegas JR, Rodríguez-Artalejo F. Alcohol consumption and all-cause mortality in older adults in Spain: an analysis accounting for the main methodological issues. Addiction. 2019;114(1):59–68.
35. Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875–90.

36. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. Jama. 2005;293(15):1861–7.

37. Pareja-Galeano H, Garatachea N, Lucia A. Exercise as a Polypill for Chronic Diseases. Prog Mol Biol Transl Sci. 2015;135:497–526.

38. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. Br J Sports Med. 2015;49(21):1414–22.